Procter & Gamble Health

₹5,716As of Sun 8 Nov 2026, 12:00 UTC

NSE:PGHLHealthcare

Country India

PE (Fwd) 25.36

TSR 10Y CAGR 25.00%

Div yield 2.71%

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.16

PE TTM 29.03

TSR TTM (3.76%)

Mkt cap ₹94.44B

ROIC —

SE Grade™

Value

Quality

Moat

—

1Y Price

Reference

₹6,098

6.67%

(63.24%)

Price above Reference Value

TTM

FYE 30 Jun INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

14.08

Revenue₹B

—

11.14

12.30

11.51

12.18

14.08

15.06

6.02%

15.59

Revenue growth%

—

10.34

(6.37)

5.80

15.59

7.00

8.07

—

73.37

Gross margin%

—

68.32

68.82

70.25

71.35

73.37

73.38

70.25

30.89

Operating margin%

—

21.77

24.06

24.24

28.17

30.89

30.96

24.24

100

23.22

Net margin%

—

17.28

18.66

17.46

20.62

23.22

23.26

18.66

100

29.03

P/E ratio (avg)x

—

41.77

32.80

41.27

33.96

28.89

27.08

33.96

21.82

EV/EBITx

—

33.15

25.44

29.71

24.87

21.72

20.34

25.44

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

100

—

Return on equity%

—

100

—

Return on assets%

—

100

196.94

EPS₹

—

115.98

138.24

121.08

151.33

196.94

211.11

14.15%

—

30.14

EPS growth%

—

19.19

(12.42)

24.99

30.14

7.20

22.09

—

Bookvalue per sh₹

—

FCF per share₹

—

155.00

Dividend per sh₹

—

52.50

95.00

110.00

166.67

155.00

163.11

31.08%

—

2.71

Div yield (avg)%

—

1.08

2.10

2.20

3.24

2.72

2.85

2.20

78.70

Payout ratio%

—

45.27

68.84

90.91

110.29

78.70

77.26

78.70

16.60

Shares (diluted)M

—

16.60

◌16.60

—

Buyback yield%

—

◌—

—

D/E ratiox

—

94.89

Enterprise value₹B

—

80.42

75.26

82.94

85.32

94.45

94.89

4.10%

—

LT debt₹M

—

Peers (US$980.8M)

Cap (US$)

Viyash Scientific…

1.079B

48.36x

Strides Pharma Science…

981.0M

14.94x

Aarti Pharmalabs…

898.1M

41.23x

SSY Group Limited

970.0M

15.06x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

790.8

544.6

Own earn%

—

Sh yield%

2.71

2.46

Owners

Insiders/Inst%

—

18.26

Short interest%

—

SBC / revenue%

0.14

Record

10Y

Profitable years

5/5

Revenue growth years

3/4

EPS growth years

3/4

Dividend streakyrs

Op margin range%

22–31

$1 testx

—

Incr. ROIC%

—

Procter & Gamble Health Limited manufactures and markets pharmaceutical and chemical products in India and internationally. It offers over-the-counter products, vitamins, minerals, and supplements under the Betamil, Polybion, Cosome, Evion, Neurobion, Seven Seas, Nasivion, and Livogen brand names. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹14.08B

6.02%

1.00×

Cost of revenue

₹3.750B

1.52%

0.84×

Operating expenses

₹5.980B

3.62%

0.91×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m